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The Medicare Drug Benefit (Part D)
The Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) established a voluntary
outpatient prescription drug benefit for Medicare beneficiaries
that began January 1, 2006. Total expenditures for the Medicare
drug benefit are projected to be $101.0 billion in 2016.1 Medicare
subsidizes the cost of the program, generally paying about
75 percent of program costs. Beneficiaries enrolling in Part D
pay a monthly premium in addition to cost sharing and any
deductible for their drugs. Low-income beneficiaries pay lower
or no premiums, cost sharing, or deductibles.
The Medicare drug benefit is administered through private
entities called prescription drug plans (PDPs) for beneficiaries in
fee-for-service (also known as original or traditional) Medicare
and through Medicare Advantage prescription drug (MA-PD)
plans for beneficiaries enrolled in Medicare managed care. PDPs
and MA-PDs perform such functions as:
• Designing and marketing drug benefit plans
• Negotiating drug prices with manufacturers and pharmacies
• Building and managing a network of pharmacies
• Paying claims
• Enrolling and disenrolling beneficiaries
• Managing a drug formulary and beneficiary appeals process
• Tracking beneficiary drug spending
Employers and unions offering retiree coverage that is at least
as generous as Medicare’s drug benefit may qualify for retiree
drug subsidies (RDS) to help defray the cost of providing a drug
benefit to their Part D–eligible retirees. (See “Employers and
Part D” section below for more on these plans.)

JANUARY 4, 2016

NATIONAL HEALTH POLICY FORUM

BEN EFI C I A RY PA RT I C I PAT I O N
Medicare beneficiaries who are eligible for Medicare Part A or enrolled
in Part B may enroll in a Medicare drug plan. In 2014, 37.9 million
beneficiaries enrolled in a PDP or MA-PD. About 61 percent are enrolled
in PDPs with the remainder obtaining coverage through Medicare
Advantage drug plans. An additional 2.6 million beneficiaries enrolled
in a drug plan through a former employer or union qualifying to receive
RDS.2 Beneficiaries can also receive drug coverage through sources
that do not receive Medicare subsidies including TRICARE, the Federal
Employees Health Benefits Program for retirees, Veterans Administration
coverage, and employer-sponsored insurance for active workers with
Medicare as a secondary payer. It is estimated that about 10 percent of
Medicare beneficiaries have no known source of drug coverage.
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BEN EFI T S T RUC T U RE
The Part D standard benefit for 2016 includes a $360 deductible, 25 percent
coinsurance for covered drug spending between $360 and $3,310, and
variable coinsurance for drug spending between $3,310 and $7,515 (a gap in
coverage popularly known as the “donut hole”).3 After $4,850 in beneficiary
true out-of-pocket (or “TrOOP”)4 spending is reached, catastrophic
coverage begins and beneficiaries are only responsible for 5 percent cost
sharing. All drug plans must offer a standard benefit plan.
The Patient Protection and Affordable Care Act (ACA), as amended
by the Health Care and Education Reconciliation Act of 2010, enacted
changes to the Medicare drug benefit, most notably reducing beneficiary
cost sharing in the coverage gap. The coverage gap changes are
implemented gradually until the gap is eliminated in 2020. In 2016,
beneficiaries will pay 45 percent of the cost for brand name drugs and
58 percent of the cost for generic drugs in the coverage gap. In 2020 and
thereafter, beneficiary cost sharing in the coverage gap for brand name
and generic drugs will be 25 percent. (FIGURE 1, next page.)
Medicare drug plans may offer nonstandard benefit plans that vary from
this standard benefit. For example, Medicare drug plan sponsors may
offer drug plans that are actuarially equivalent to the Medicare drug
benefit. They may also offer plans that are more generous, or enhanced,
as long as they also offer a basic benefit package. Nonstandard plans
are popular with beneficiaries because they may have lower deductibles
or cost sharing, albeit generally at higher premiums. The majority of
beneficiaries are enrolled in nonstandard plans.
www.nhpf.org
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FIGURE 1: Standard Drug Benefit Design, 2016
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Source: Kaiser Family Foundation, “The
Medicare Prescription Drug Benefit,” Fact
Sheet, October 2015, http://kff.org/medicare/
fact-sheet/the-medicare-prescription-drugbenefit-fact-sheet.

BEN EFI C I A RY P REM I U M S A N D PL A N PAY M EN T S
Beneficiaries enrolled in PDPs typically pay a monthly premium
for Medicare prescription drug coverage. Beneficiary premiums are
determined by bids submitted by drug plans. A base premium of 25.5
percent of the national average of all bids is computed. The premium
for an individual drug plan is the sum of the base premium and the
difference between the plan’s bid and the national average of all bids.
Beneficiaries joining plans with bids above the national average pay
more than the base premium, and those joining plans with bids below
the national average pay less than the base premium with a floor of no
premium. Medicare Advantage plans have flexibility to allocate premium
dollars between the drug benefit and other health benefits they offer. As
a result, many Medicare Advantage plans are able to offer drug coverage
for $0 premium. They are also more likely than PDPs to offer coverage in
the gap and a $0 deductible. In 2016, the average5 monthly premium for
stand-alone PDPs is projected to be $41.46; the range of premiums is $11.40
to $174.70. Beneficiaries with incomes higher than $85,000 ($170,000 for
couples) will also pay a monthly surcharge ranging from $12.70 to $72.90.
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In addition to receiving beneficiary premiums (estimated to amount
to $14.4 billion in 20166), Medicare drug plans receive payments
from Medicare to subsidize the cost of providing the benefit. Direct
premium payments represent Medicare’s major subsidy to plans for all
beneficiaries (an estimated $19.5 billion in 2016). Reinsurance subsidizes
catastrophic expenses (an estimated $35.7 billion in 2016). Low-income
subsidy payments subsidize premium and cost-sharing assistance for
low-income beneficiaries (an estimated $26.4 billion in 2016).7

A SSI S TA N CE F O R LOW - I N CO M E BEN EFI C I A RI ES
About 29 percent of Part D enrollees are expected to qualify for
assistance in paying premiums, deductibles, and cost sharing in 2016.8
These individuals have incomes below 150 percent of the federal poverty
level ($17,655 for an individual and $23,895 for a couple in 2015)9 and
few assets, and include beneficiaries dually eligible for Medicare and
Medicaid (often referred to as “dual eligibles”). The level of extra benefits
Medicare provides depends on the person’s income: lower income
individuals receive more generous extra benefits including no or low
premiums, deductibles, and cost sharing. The lowest income beneficiaries,
dual eligibles, pay no premiums for drug plans with premiums below
the average in an area, only very modest cost sharing for prescriptions,
no deductible, and are not subject to the coverage gap.
Private plans are paid extra by Medicare for low-income enrollees to
compensate for the additional benefits they receive. Private plans will
be paid an estimated $1,333 per enrollee for drug benefits in 2016, and an
additional $2,141 per low-income enrollee.10
Many low-income beneficiaries, including dual eligibles, received drug
coverage through Medicaid prior to the implementation of the Medicare
drug benefit in 2006. In order to help finance their participation in Part
D, the MMA requires states to contribute 90 percent of the expected
state cost of drugs for this population, phasing down over 10 years to
75 percent. This provision is commonly called the “clawback.” State
payments are expected to total $9.8 billion in 2016.11

EM PLOY ER S A N D PA RT D
Employers have several options for interacting with the Medicare drug
benefit. Employers and union groups that provide prescription drug
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insurance to their Medicare-eligible retired workers that is at least a
generous as Part D coverage may apply to receive retiree drug subsidies
(RDS) from Medicare. These payments are intended to help employers
maintain drug coverage for their retirees, and are less expensive for
Medicare than enrolling these beneficiaries in a Part D drug plan. In 2016
the average RDS payment is projected to be about $659 per beneficiary.12
Beginning in 2013, these payments were no longer tax-free for taxpaying
employers. Employers not receiving the retiree drug subsidy may choose
to “wrap around” Part D coverage by paying Part D premiums or
contributing toward deductibles and/or cost sharing for their retirees.

F O RM U L A RIES A N D A P PE A L S
The law permits Medicare drug plans to pay for most drugs approved
by the Food and Drug Administration (FDA). However, virtually all
PDPs use formularies, or lists of covered drugs, that effectively limit
the number and type of drugs paid for by the plan. Plans are required
to include a relatively broad range of drugs on their formularies to
help prevent a plan from systematically discouraging beneficiaries
with certain health conditions from enrolling. Plans are also prohibited
from limiting drugs in certain protected classes, which include
anticonvulsants, antidepressants, antineoplastics, antipsychotics,
antiretrovirals, and immunosuppressants for the treatment of transplant
rejection. Beneficiaries may appeal the decision of a plan to not pay (or
require a higher copayment) for a particular drug.
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